A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies

Authors :: Jacqueline Ramírez
Larry House
Gini F. Fleming
Michael L. Maitland
Ezra E.W. Cohen
Mark J. Ratain
Tara Gangadhar
Samir D. Undevia
Linda Janisch
Source :: Journal of Clinical Oncology. 26:2545-2545
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 2545 Background: R inhibits the mammalian target of rapamycin (mTOR) and is active in preclinical tumor models. S inhibits multiple kinases. S and mTOR inhibitors have activity in similar tumor typ...

Subjects :: Sorafenib
Cancer Research
Oncology
business.industry
Kinase
Medicine
In patient
Pharmacology
Drug interaction
business
Discovery and development of mTOR inhibitors
PI3K/AKT/mTOR pathway
medicine.drug

Tools